BÜHLMANN Laboratories

BÜHLMANN Laboratories is a Swiss specialty in vitro diagnostics company focused on non-invasive and near-patient testing for gastrointestinal disease, therapeutic drug monitoring, cellular allergy, and selected neuroimmunology applications. The company develops, manufactures, and commercializes proprietary IVD and RUO assays, including market-leading fecal calprotectin products, pancreatic elastase tests, basophil activation assays, and rapid tests for biologic drug monitoring. Its portfolio includes laboratory ELISA and immunoturbidimetric assays, point-of-care and home-testing solutions, and sample-preparation devices such as CALEX Cap. BÜHLMANN sells globally through subsidiaries and distribution partners and has built open-system collaborations with major instrument manufacturers to broaden menu placement on routine chemistry platforms. The company is private and, since June 5, 2024, has been owned by funds advised by KLAR Partners.